Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20323441 | 0.78 | CHRM4 (0.39) | KDM4EALDH1A1CHRM4SCDLMNA | |
| SCHEMBL20303140 | 0.77 | CHRM4 (0.56) | KDM4EALDH1A1SMN1; SMN2CHRM4PIM1 | |
| SCHEMBL20303040 | 0.77 | CHRM4 (0.53) | CHRM4SCD | |
| SCHEMBL20303188 | 0.72 | CHRM4 (0.49) | CHRM4SCD | |
| SCHEMBL20302590 | 0.72 | CHRM4 (0.61) | CHRM4SCD | |
| SCHEMBL20323440 | 0.69 | SMN1; SMN2 (0.31) | KDM4EALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL20302466 | 0.66 | HCRTR2 (0.46) | KDM4EALDH1A1SMN1; SMN2CHRM4PIM1 | |
| SCHEMBL12285955 | 0.66 | SCD (0.58) | KDM4EALDH1A1SMN1; SMN2CHRM3PDE4A | |
| SCHEMBL1400767 | 0.64 | HCRTR2 (0.47) | KDM4EALDH1A1SMN1; SMN2PIM1CHRM3 | |
| SCHEMBL19023311 | 0.63 | CHRM4 (0.60) | KDM4EALDH1A1SMN1; SMN2CHRM4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3558306-B1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3558306-B1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200095261-A1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2020-03-26 | — | — | US | disclosed |
| EP-3558306-A1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118736-A1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018112840-A1 | 6, 5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118736-A1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM2 | KDM4E 748/4885ALDH1A1 3051/4885SMN1; SMN2 2700/4885 |
| US-20200095261-A1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM5, CHRM4, CHRM2 | KDM4E 748/4885ALDH1A1 3051/4885SMN1; SMN2 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.